NanoViricides Highlights NV-387 as Potential Candidate for Bundibugyo Ebola Outbreak

NanoViricides, Inc. (NYSE American: NNVC) has announced that its broad-spectrum antiviral drug candidate NV-387 warrants evaluation as a potential treatment for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company highlighted that there are currently no approved vaccines or therapies specifically targeting this virus strain, underscoring the urgent need for effective interventions.

NV-387 employs a host-targeted antiviral mechanism, which could provide broad-spectrum activity against multiple viral pathogens. Additionally, its oral formulation may offer significant advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. The drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola.

NanoViricides noted that the same host-targeted approach could potentially circumvent the challenges of viral mutations that often render direct-acting antivirals ineffective. The company's lead drug candidate, NV-387, is also being developed for respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other viral infections, including mpox and smallpox.

The announcement comes as the Bundibugyo Ebola outbreak continues to spread, with no specific treatments or vaccines available. According to the company, NV-387's mechanism of action targets host cell processes required for viral replication, making it less likely to be impacted by viral genetic diversity. This could be particularly valuable for emerging viral threats where rapid deployment is essential.

NanoViricides' technology is based on nanomedicine platforms licensed from TheraCour Pharma, Inc. The company holds exclusive licenses for several antiviral applications, including Ebola and Marburg viruses. However, the company cautions that drug development is inherently risky and requires substantial capital, with no assurance of successful clinical trials or regulatory approval.

For more information, visit the company's newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/aSF5Z.